阿帕蒂尼
医学
内科学
不利影响
肝细胞癌
胃肠病学
置信区间
索拉非尼
耐火材料（行星科学）
无进展生存期
临床研究阶段
外科
临床终点
临床试验
癌症
总体生存率
物理
天体生物学
作者
Jianming Xu,Jie Shen,Shanzhi Gu,Yun Zhang,Lihua Wu,Jian Wu,Guoliang Shao,Yanqiao Zhang,Li Xu,Tao Yin,Jingfeng Liu,Zhenggang Ren,Jianping Xiong,Xianhai Mao,Ling Zhang,Jiayin Yang,Le‐Qun Li,Xiaohong Chen,Zhiming Wang,Kangsheng Gu
标识
DOI：10.1158/1078-0432.ccr-20-2571
摘要
Camrelizumab combined with apatinib showed promising efficacy and manageable safety in patients with advanced HCC in both the first-line and second-line setting. It might represent a novel treatment option for these patients.See related commentary by Pinato et al., p. 908.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
嘻嘻哈哈
cdercder
潇洒的惋清
GingerF
lalala
AllRightReserved
学术文献互助
无极微光
iNk
糊涂的雅琴
sanvva
OK
碎觉觉
小牛马阿欢
Scorpia112
duanwy
HFH
互助
尊嘟假嘟
昏睡的蟠桃
皖公网安备34019202002308
